Preserving the Gift of Life Against Cancer's Challenges
Colorado Springs, CO
“It is the tension between creativity and skepticism that has produced the stunning and unexpected findings of science.”
– Carl Sagan
A new and promising potential treatment for cancer
In the past 50 years, over $100 billion has been spent on cancer research by the National Cancer Institute, with much more from private firms. Yet, cancer remains the second leading cause of death, with mortality rates unchanged. Immunotherapy, hailed as a breakthrough, treats only 8% of cancers and costs up to $1 million per patient, making it unviable even for those it could help.
Lahjavida has made progress in targeting lung, breast, and colon cancer cells with a drug that combines a tumor-targeting dye, unique linkers, and "Standard of Care" chemotherapy. This drug activates inside cancer cells, destroying them while being minimally toxic to healthy tissue. We are now seeking $5.2 million to confirm and improve these results in animal models by 2024 and ultimately aim to raise $15 million for human trials by 2026 or 2027.
​
WHY LAHJAVIDA
​
Lahjavida, Inc. is a cancer research venture with a vision to improve and extend the gift of life for patients. Our patented technologies utilize the unique tumor-targeting capabilities of special fluorescing dyes, in conjunction with "standard-of-care" chemotherapy drugs. This treatment promises to enhance the effectiveness of the therapy, while preserving healthy tissues. The tumor-targeting dyes act as the delivery mechanism for the drugs, while ensuring that the drugs are "turned off" until the Lahjavida compounds reach the tumor site. Once there, our unique linker system "dissolves", releasing the drug and activating it. This technology allows for a more effective, less toxic, and a better way to deliver drugs exactly where they are needed, while protecting healthy tissues from the toxic impact of traditional chemotherapy. These dyes bind to over 30 different cancer types, holding tremendous promise for future treatments. Most importantly, this solution will potentially treat metastatic cancers, which pose the most serious dangers to patients. This is not a dream. Lahjavida has pre-clinical data supporting all of these claims. We are on the doorstep of a breakthrough in cancer treatment. Join us in improving and extending the gift of life for millions of future cancer patients.
SUMMARY
​
Lahjavida has shown significant progress in cancer treatment. We can precisely target lung, breast, and colon cancer cells using a drug design with a tumor-targeting dye, special linkers, and standard chemotherapy drugs. This drug activates inside cancer cells, destroying them while remaining minimally toxic to healthy tissue.
​
Our research demonstrates that standard chemotherapy drugs can be attached to tumor-targeting dyes via cleavable linkers. In animal models, this combination reliably targets tumors, with linkers designed to cleave only in the cancer cell environment. Data shows cancer cells begin to die within 8 days of injection.
FUNDING
​
We now are ready to raise $5.2MM, to confirm these initial results and improve on them, with the goal of reducing or eliminating cancer in an animal model in 2024 and ultimately raising up to $15MM in order to qualify for human trials in 2026 or 2027.
We need funding to show that the compound will accumulate in the tumors of mice at large enough doses to treat the animal, and to demonstrate that our radiowave machine will heat up the gold while inside the animal. We need continuous funding to enable UC Denver and UCCS to do this work.
Lahjavida will create and manufacture the required compound as part of its investment in the effort.